💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Fosnetupitant

CHEMBL3989917 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
688.6 g/mol
LogP
5.0
Phase
4

A prodrug of netupitant, a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting, particularly delayed nausea. After intravenous administration, it is rapidly converted to netupitant which blocks substance P from triggering nausea signals in the brain. It is often combined with a 5-HT3 antagonist for broader antiemetic coverage.

आणविक भार

688.6000 g/mol

LogP

5.00

TPSA

106.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

क्रिया का तंत्र

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C31H35F6N4O5P/c1-20-8-6-7-9-24(20)25-17-27(40-10-12-41(5,13-11-40)19-46-47(43,44)45)38-18-26(25)39(4)28(42)29(2,3)21-14-22(30(32,33)34)16-23(15-21)31(35,36)37/h6-9,14-18H,10-13,19H2,1-5H3,(H-,43,44,45)

                

                

                

                    
                    

                        
Molecular Formula

                        
C31H35F6N4O5P

                    

                    
                    

                        
HBD / HBA

                        
1 / 13

                    

                    
                    

                        
घूर्णनीय बंधन

                        
8

                    

                    
                    
                    

                        
भारी परमाणु

                        
47

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
A prodrug of netupitant, a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting, particularly delayed nausea. After intravenous administration, it is rapidly converted to netupitant which blocks substance P from triggering nausea signals in the brain. It is often combined with a 5-HT3 antagonist for broader antiemetic coverage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Fosnetupitant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3989917.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 71544786.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.